AU2022219921A1 - Oncolytic virus for systemic delivery and enhanced anti-tumor activities - Google Patents
Oncolytic virus for systemic delivery and enhanced anti-tumor activities Download PDFInfo
- Publication number
- AU2022219921A1 AU2022219921A1 AU2022219921A AU2022219921A AU2022219921A1 AU 2022219921 A1 AU2022219921 A1 AU 2022219921A1 AU 2022219921 A AU2022219921 A AU 2022219921A AU 2022219921 A AU2022219921 A AU 2022219921A AU 2022219921 A1 AU2022219921 A1 AU 2022219921A1
- Authority
- AU
- Australia
- Prior art keywords
- hsv
- oncolytic
- glycoprotein
- composition
- fuson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163200011P | 2021-02-09 | 2021-02-09 | |
| US63/200,011 | 2021-02-09 | ||
| US202163263528P | 2021-11-04 | 2021-11-04 | |
| US63/263,528 | 2021-11-04 | ||
| PCT/US2022/015703 WO2022173767A1 (en) | 2021-02-09 | 2022-02-08 | Oncolytic virus for systemic delivery and enhanced anti-tumor activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022219921A1 true AU2022219921A1 (en) | 2023-06-29 |
Family
ID=80623426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022219921A Pending AU2022219921A1 (en) | 2021-02-09 | 2022-02-08 | Oncolytic virus for systemic delivery and enhanced anti-tumor activities |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240123004A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291216A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024508088A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022219921A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3202849A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022173767A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230295661A1 (en) * | 2022-03-16 | 2023-09-21 | University Of Houston System | Persistent hsv gene delivery system |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| DK0604662T3 (da) | 1992-07-07 | 2008-10-20 | Japan Tobacco Inc | Fremgangsmåde til transformering af monocotyledon |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| AU670316B2 (en) | 1992-07-27 | 1996-07-11 | Pioneer Hi-Bred International, Inc. | An improved method of (agrobacterium)-mediated transformation of cultured soybean cells |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US6013265A (en) | 1996-10-22 | 2000-01-11 | University Of Maryland, Baltimore | Vaccine composition for herpes simplex virus and methods of using |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| US8986672B2 (en) * | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| US20150246086A1 (en) | 2005-06-23 | 2015-09-03 | The University Of Houston System | Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy |
| WO2012071276A1 (en) | 2010-11-23 | 2012-05-31 | Xiaoliu Zhang | Oncolytic virus as an inducer for innate antitumor immunity |
| EP3400291B2 (en) * | 2016-01-08 | 2024-02-28 | Replimune Limited | Engineered virus |
| ES2976558T3 (es) * | 2017-06-21 | 2024-08-05 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas |
| CN112368007A (zh) * | 2018-05-31 | 2021-02-12 | 高等教育联邦系统-匹兹堡大学 | 抗原隐匿的溶瘤病毒 |
-
2022
- 2022-02-08 WO PCT/US2022/015703 patent/WO2022173767A1/en not_active Ceased
- 2022-02-08 JP JP2023541092A patent/JP2024508088A/ja active Pending
- 2022-02-08 EP EP22707286.5A patent/EP4291216A1/en active Pending
- 2022-02-08 CA CA3202849A patent/CA3202849A1/en active Pending
- 2022-02-08 US US18/264,737 patent/US20240123004A1/en active Pending
- 2022-02-08 AU AU2022219921A patent/AU2022219921A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3202849A1 (en) | 2022-08-18 |
| EP4291216A1 (en) | 2023-12-20 |
| US20240123004A1 (en) | 2024-04-18 |
| WO2022173767A1 (en) | 2022-08-18 |
| JP2024508088A (ja) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10039796B2 (en) | Mutant herpes simplex virus-2 for cancer therapy | |
| AU2003258060B2 (en) | Potent oncolytic herpes simplex virus for cancer therapy | |
| US12414973B2 (en) | Antigenically stealthed oncolytic viruses | |
| US20240123004A1 (en) | Oncolytic virus for systemic delivery and enhanced anti-tumor activities | |
| US20150246086A1 (en) | Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy | |
| MXPA02002142A (es) | Promotor especifico de la celula y/o especifico del tumor, que re-selecciona como objetivo la expresion del gen gamma 35.5 de herpes. | |
| JP7460850B2 (ja) | 多重標的化組換えヘルペスシンプルレックスウイルス及びその用途 | |
| CN116782917A (zh) | 用于全身递送的溶瘤病毒及增强的抗肿瘤活性 | |
| US20230295661A1 (en) | Persistent hsv gene delivery system | |
| WO2026101618A2 (en) | Attenuated oncolytic virus and uses thereof |